BTLA/CD272 Antibody (2161A) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: Flow
• Clone: 2161A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 700

BTLA/CD272 Antibody (2161A) [Alexa Fluor® 700] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line, NS0-derived human BTLA
  Ile25-Ser150
  Accession # AAP44003
• Specificity: Detects human BTLA in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BTLA/CD272 Antibody (2161A) [Alexa Fluor® 700]

• B and T lymphocyte associated
• B and T lymphocyte attenuator
• B- and T-lymphocyte attenuator
• B- and T-lymphocyte-associated protein
• BTLA
• BTLA1
• CD272 antigen
• CD272
• FLJ16065
• MGC129743

Background

B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell co-stimulatory molecules (1-3). Mature human BTLA contains a 127 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane sequence, and a 111 aa cytoplasmic domain. The two ITIM motifs and three Tyr phosphorylation sites in the cytoplasmic tail transmit inhibitory signaling (4-5). The ECD of human BTLA shares 42% and 44% aa identity with that of mouse and rat BTLA, respectively. A splice variant lacking the transmembrane domain has been reported (6). Unlike other CD28 family members, the BTLA Ig domain in the ECD is of the I-type rather than V-type, and BTLA does not form homodimers (7). BTLA is also unusual in its interaction with the TNF superfamily member HVEM rather than with B7 family ligands (8). BTLA is expressed on T cells, B cells, macrophages, dendritic cells, and NK cells (9). Its expression is low in naïve T cells and increases during antigen-specific induction of anergy. In B cells, BTLA expression is highest in mature naïve cells (9). BTLA apparently limits T cell numbers, since its deletion results in overproduction of T cells, especially CD8⁺ memory T cells that are hyper-responsive to TCR cross-linking (10). Under the control of ROR gamma t and IL-7, BTLA regulates the homeostasis and inflammatory responses of gamma δT cells (11). The binding of BTLA and HVEM does not preclude the concurrent binding of other HVEM ligands such as LIGHT or Lymphotoxin-alpha (12).

1. Murphy, K.M. et al. (2006) Nat. Rev. Immunol. 6:671.
2. Croft, M. (2005) Trends. Immunol. 26:292.
3. Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
4. Gavrieli, M. et al. (2003) Biochem. Biophys. Res. Commun. 312:1236.
5. Chemnitz, J.M. et al. (2006) J. Immunol. 176:6603.
6. Han, P. et al. (2004) J. Immunol. 172 :5931.
7. Compaan, D.M. et al. (2005) J. Biol. Chem. 280:39553.
8. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
9. Hurchla, M.A. et al. (2005) J. Immunol. 174:3377.
10. Krieg, C. et al. (2007) Nat. Immunol. 8:162.
11. Bekiaris, V. et al. (2013) Immunity 39:1082.
12. Cai G and Freeman GJ, (2009) Immunol Rev. 229:244

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • AAP44003()